Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography (NORDICA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02263820|
Recruitment Status : Completed
First Posted : October 13, 2014
Last Update Posted : August 17, 2018
Contrast-induced acute kidney injury (CI-AKI) has been recognized as the third most common cause of hospital acquired AKI, after hypotension-associated hypo-perfusion and post-operative AKI. The development of CI-AKI after cardiac catheterization is associated with a significant increase in both short-term and long-term mortality and morbidities, as well as an increase in length of stay and cost.
The only marker of renal function that has predictive ability is creatinine and it has significant limitations in identifying patients who will develop AKI. Therefore, a diagnostic test for predicting CI-AKI risk would have widespread clinical utility.
The primary purpose of this study is to measure the association between baseline expression of senescence markers in blood using SenesceTest and the occurrence of CI-AKI post cardiac catheterization.
|Condition or disease|
|Acute Kidney Injury Renal Insufficiency Kidney Diseases|
|Study Type :||Observational|
|Actual Enrollment :||185 participants|
|Official Title:||Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography (NORDICA Study)|
|Study Start Date :||January 2015|
|Actual Primary Completion Date :||July 2016|
|Actual Study Completion Date :||December 2016|
- Changes in serum creatinine levels (absolute and percentage) [ Time Frame: Measured 48-72h after catheterization ]
- Major Adverse Clinical Events (MACE, a composite of all-cause mortality, myocardial infarction or renal replacement therapy) [ Time Frame: Within 90 days after catheterization ]
- Admission to the ICU [ Time Frame: Within 90 days after catheterization ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02263820
|United States, North Carolina|
|UNC Center for Heart & Vascular Care|
|Chapel Hill, North Carolina, United States, 27599|
|Principal Investigator:||George A Stouffer, MD||University of North Carolina|